PLC continues to support the Regulatory filings and the Clinical Trial operations for ARS Pharmaceuticals as they successfully advance the development of ARS-1. ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine